Advertisement
*
Reproduction permitted for personal use only. For reprints and reprint permission, contact reprints@wistechnology.com.

Midwest biotech stocks receive hefty haircut in first half of 2005

When we met last week, we reviewed the performance of the Midwest large cap life science group of companies in the context of how the overall stock market indices reacted during the first half of 2005.

The message was that the major indices were substantially down (as can be seen below) with the exception of the Amex Biotech index. In spite of this general market malaise, a number of Midwest companies were up on a very solid basis.



For this week, it’s time to take a look at the smaller cap Midwest biotech publicly traded companies to gauge the sector performance. Let’s see how we did:

Advertisement


At least there are a handful of companies that outperformed both the biotech indices as well as the other major indices. Aastrom Biosciences saw a significant increase in its stock price. The company seems to be capitalizing on the rising tide of interest in stem-cell therapy research, which is in the public eye due to the major commitments in research by a number of states.



Misery loves company, eh? What a haircut our Midwest biotech stocks took in the first half of the year.

It’s virtually an across-the-board haircut that affected medical devices, specialty pharma, drug delivery and conventional biotech alike. Granted, many of the larger cap biotech stocks weathered the storm, but we have a few companies in the $2 billion range that also got short-circuited.

While this isn’t a pretty picture, this is only the mid-year point (and of course oil prices keep rising). See you next week when we will focus on the progress of venture capital funding in the life science space in the first half of 2005.

Michael S. Rosen is president of Rosen Bioscience Management, a company that provides CEO services including financing, business and corporate development to start-up and early stage life science companies such as Renovar and Immune Cell Therapy. Rosen is also a founder and board member of the Illinois Biotechnology Industry Organization. He can be reached at rosenmichaels@aol.com.

This article has been syndicated on the Wisconsin Technology Network courtesy of ePrairie, a user-driven business and technology news community distributed via the Web, the wireless Web and free daily e-mail newsletters.

The opinions expressed herein or statements made in the above column are solely those of the author and do not necessarily reflect the views of The Wisconsin Technology Network, LLC. (WTN). WTN, LLC, accepts no legal liability or responsibility for any claims made or opinions expressed herein.

-Add Your Comment

Name:
E-mail:

Comment Policy: WTN News accepts comments that are on-topic and do not contain advertisements, profanity or personal attacks. Comments represent the views of the individuals who post them and do not necessarily represent the views of WTN Media or our partners, advertisers, or sources. Comments are moderated and are not immediately posted. Your email address will not be posted.

WTN Media cannot accept liability for the content of comments posted here or verify their accuracy. If you believe this comment section is being abused, contact edit@wistechnology.com.

WTN Media Presents